Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

59.40EUR
11:35am EST
Change (% chg)

€-0.60 (-1.00%)
Prev Close
€60.00
Open
€60.30
Day's High
€60.80
Day's Low
€59.20
Volume
80,948
Avg. Vol
113,193
52-wk High
€82.60
52-wk Low
€59.00

Latest Key Developments (Source: Significant Developments)

Biomérieux Acquires A Majority Stake In Hybiome
Friday, 9 Nov 2018 01:00am EST 

Nov 9 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX ACQUIRES A MAJORITY STAKE IN HYBIOME AND STRENGTHENS ITS PRESENCE BOTH IN CHINA AND IN THE IMMUNOASSAY MARKET.ACQUISITION OF 54% OF SHARES OF HYBIOME RELIES ON A EUR 165 MILLION VALUATION, ON TOP OF WHICH ADDITIONAL EXPENSES OF 25 MILLION EUROS WERE INCURRED AS CONSIDERATION FOR ADDITIONAL ASSETS.  Full Article

Biomerieux 9-Month Sales Up At 1.75 Billion Euros
Thursday, 18 Oct 2018 01:00am EDT 

Oct 18 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX – BUSINESS REVIEW FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2018.9M EUR 1,749 MILLION IN SALES UP 4.5% AS REPORTED.ON TRACK TO ACHIEVING ITS FINANCIAL OBJECTIVES FOR YEAR.  Full Article

Biomerieux Launches Endozyme II Go
Thursday, 31 May 2018 01:00am EDT 

May 31 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX LAUNCHES ENDOZYME® II GO, A TEST FOR THE DETECTION OF ENDOTOXINS IN PHARMACEUTICAL MICROBIOLOGY CONTROL.  Full Article

Biomerieux FY Sales Up At 2.29 Billion Euros
Wednesday, 28 Feb 2018 02:02am EST 

Feb 28 (Reuters) - BIOMERIEUX SA ::FY SALES EUR 2.29 BILLION VERSUS EUR 2.10 BILLION YEAR AGO.FY OPERATING INCOME EUR 315 MILLION VERSUS EUR 282 MILLION YEAR AGO.FY RESULT EUR 238 MILLION VERSUS EUR 179 MILLION YEAR AGO.FOR 2018 EXPECTS ORGANIC SALES GROWTH OF BETWEEN 8 AND 9 PERCENT, AT CONSTANT EXCHANGE RATES AND PERIMETER.FOR 2018 EXPECTS CONTRIBUTING CURRENT OPERATING INCOME OF BETWEEN € 325 AND € 345 MILLION.TO PROPOSE A DIVIDEND OF EUR 0.34 PER SHARE.  Full Article

Biomerieux Q3 sales up at ‍​1.67 billion euros
Wednesday, 18 Oct 2017 01:01am EDT 

Oct 18 (Reuters) - BIOMERIEUX SA ::Q3 SALES EUR ‍​1.67 BILLION VERSUS EUR 1.51 BILLION YEAR AGO.  Full Article

Biomerieux H1 operating income rises to 163 million euros
Wednesday, 30 Aug 2017 01:18am EDT 

Aug 30 (Reuters) - BIOMERIEUX SA ::IS NOW TARGETING ORGANIC SALES GROWTH FOR FULL YEAR OF BETWEEN 9 PCT AND 10 PCT.EUR 1,134 MILLION IN SALES ‍​IN H1, UP 13.3 PCT AS REPORTED.IS NOW AIMING TO DELIVER FULL-YEAR CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS OF BETWEEN EUR 330 MILLION AND EUR 345 MILLION.IN H1 18 PCT INCREASE IN NET INCOME TO EUR 101 MILLION.2017 FINANCIAL TARGETS REVISED: ORGANIC GROWTH IN SALES OF BETWEEN 9 PCT AND 10 PCT ‍​.H1 OPERATING INCOME EUR 163 MILLION VERSUS EUR 146 MILLION YEAR AGO.  Full Article

Biomérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS
Monday, 31 Jul 2017 01:01am EDT 

July 31 (Reuters) - BIOMERIEUX SA : :BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR EXPANDED PATHOGEN IDENTIFICATION CAPABILITY ON VITEK® MS.  Full Article

Sysmex and Biomérieux agreed to dissolve JV Sysmex Biomérieux co., ltd.
Thursday, 27 Jul 2017 02:01am EDT 

July 27 (Reuters) - BIOMERIEUX SA : :SYSMEX AND BIOMÉRIEUX AGREED TO DISSOLVE THE JOINT VENTURE SYSMEX BIOMÉRIEUX CO., LTD..‍SYSMEX AND BIOMÉRIEUX HAVE AGREED TO TRANSFER ALL OF SYSMEX' HOLDINGS IN SYSMEX BIOMÉRIEUX TO BIOMÉRIEUX​.SYSMEX WILL TRANSFER ALL OF ITS HOLDINGS IN SYSMEX BIOMÉRIEUX (34% OF SHARES) TO BIOMÉRIEUX.‍DISTRIBUTION AGREEMENT RELATING TO DISTRIBUTION OF BIOMÉRIEUX PRODUCTS IN JAPAN BETWEEN SYSMEX AND SYSMEX BIOMÉRIEUX WILL ALSO TERMINATE AS OF OCTOBER 31, 2017​.‍SYSMEX WILL CONTINUE TO PROVIDE CUSTOMER SERVICE IN JAPAN FOR BIOMÉRIEUX PRODUCTS UNTIL MARCH 31, 2018​.‍SHARE TRANSFER DATE OCTOBER 31, 2017 (SCHEDULED)​.  Full Article

Biomerieux H1 sales up at 1,134 million euros
Thursday, 20 Jul 2017 01:10am EDT 

July 20 (Reuters) - BIOMERIEUX SA ::SALES UP 11.3% OVER FIRST HALF AT CONSTANT EXCHANGE RATES AND SCOPE OF CONSOLIDATION​.H1 €1,134 MILLION IN SALES‍​.‍FOR 2017 CONFIDENT THAT IT WILL ACHIEVE HIGHER END OF ITS TARGET ORGANIC SALES GROWTH RANGE OF BETWEEN 8% AND 9%​.  Full Article

Biomerieux receives FDA clearance for BioFire’s FilmArray Respiratory Panel 2 (RP2)
Thursday, 1 Jun 2017 01:00am EDT 

June 1 (Reuters) - BIOMERIEUX SA ::BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR BIOFIRE’S FILMARRAY RESPIRATORY PANEL 2 (RP2).BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR BIOFIRE'S FILMARRAY RESPIRATORY PANEL 2 (RP2).‍FILMARRA RP2 REDUCES SAMPLE-TO-RESULT TIME TO ONLY 45 MINUTES WHILE ENHANCING PATHOGEN COVERAGE AND OVERALL SENSITIVITY​.FILMARRAY RP2 REDUCES SAMPLE-TO-RESULT TIME TO ONLY 45 MINUTES WHILE ENHANCING PATHOGEN COVERAGE AND OVERALL SENSITIVITY.‍FOLLOWS ANNOUNCEMENT IN APRIL THAT FILMARRAY(®) RESPIRATORY PANEL 2 PLUS (RP2PLUS) IS CE MARKED​.  Full Article

Hologic loses bid to dismiss bioMerieux's HIV test patent case

Diagnostic testing company bioMerieux SA can move forward with a lawsuit alleging that HIV testing kits manufactured by rival Hologic Inc infringe two of its patents, a federal judge in Delaware has ruled.